Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Martin MetzenmacherFilippo RizzoKato KambartelJens Peter PanseDiana SchauflerMatthias SchefflerIvo AzehMatthias SchefflerAmin T TurkiJudith AtzHannes BuchnerChristopher M HoffmannDaniel C ChristophPublished in: Future oncology (London, England) (2021)
Aim: This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Methods: Data were sourced retrospectively from seven German centers. Results: Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. Conclusion: To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy-immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.
Keyphrases
- locally advanced
- idiopathic pulmonary fibrosis
- interstitial lung disease
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- radiation therapy
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- rheumatoid arthritis
- systemic sclerosis
- drug delivery
- cancer therapy
- patient reported
- free survival